Activist investor Starboard Value has acquired a $1 billion stake in Pfizer and is seeking changes to revamp the pharmaceutical giant’s performance. Sources familiar with the matter say Starboard has approached former Pfizer executives Ian Read and Frank D’Amelio for potential involvement. Pfizer shares rose 2.2% in premarket trading, although the company has struggled with declining sales of its COVID-19 products and disappointing launches of new treatments like its RSV vaccine. Wall Street analysts remain skeptical about the immediate impact of Starboard’s involvement.
Pfizer has seen a significant decline in revenue from its COVID-19 vaccine and pill, causing shares to drop over 13% in the past year. Wall Street analysts are cautious about quick fixes, with Leerink Partners analyst David Risinger noting that there may not be an easy solution to boosting shareholder value. CEO Albert Bourla’s strategy has involved acquisitions worth nearly $70 billion, including Seagen, Biohaven, and Global Blood Therapeutics. However, these moves have yet to replace lost COVID-era revenues.
Starboard’s Involvement and Previous Influence
Starboard Value is known for pushing for changes in major companies and has been involved in notable corporate actions at News Corp, Salesforce, and Match Group. The firm’s involvement in Pfizer may signal a shift in strategy, but analysts emphasize that Starboard may face challenges given Pfizer’s current trajectory. Pfizer’s lack of a new blockbuster product, along with the underperformance of its recent acquisitions, has left the company searching for a strategy to regain momentum.
While Starboard’s $1 billion stake brings attention to Pfizer’s future, the company faces significant challenges in replacing lost COVID product revenue and finding new profitable ventures. Investors and analysts will closely watch how Starboard’s involvement and any changes to leadership or strategy play out.
